Eli Lilly and Company

Sheng-Hung Rainbow Tschang

Wolfgang Glaesner

Radmila Micanovic

Ying Tang

Jirong Lu

Derrick Ryan Witcher

Ling Liu

Barrett Allan

Rohn Lee Millican, Jr

John Edward Hale

Gerald W Becker

Radhakrishnan Rathnachalam

Pia Pauliina Yachi

Hector Aldaz

Timothy Wayne Noblitt

Fredric Jay Cohen

Yu Tian

Patricia Ann Gonzalez-DeWhitt

Christy Michelle Newton

Victor John Wroblewski

Radmilla Micanovic

Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.

Multifunctional antibodies binding to EGFR and MET

The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.

FGF-21 fusion proteins

The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.

GLP-1 fusion proteins

Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.

Flint polypeptide analogs

Growing community of inventors

Carmel, IN, United States of America

Sheng-Hung Rainbow Tschang